Yellow fever virus envelope protein expressed in insect cells is capable of syncytium formation in lepidopteran cells and could be used for immunodetection of YFV in human sera

Virology Journal

Volumn 8, Issue , 2011, Pages

  Barros, Maria C E S ^a   Galasso, Tatiane G C M ^a   Chaib, Antônio J M ^b   Degallier, Nicolas ^c   Nagata, Tatsuya ^a   Ribeiro, Bergmann M ^a  

^a UNIVERSITY OF BRASILIA   (Brazil)

^b Laboratório de Micologia do Núcleo de Parasitologia e Micologia NPM   (Brazil)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ENVELOPE PROTEIN; DIAGNOSTIC AGENT; RECOMBINANT PROTEIN; VIRUS ANTIBODY; VIRUS ANTIGEN; YELLOW FEVER VIRUS ENVELOPE PROTEIN E;

ANTIGENICITY; ARTICLE; AUTOGRAPHA CALIFORNICA; BACULOVIRUS; CONFOCAL MICROSCOPY; CROSS REACTION; CYTOPATHOGENIC EFFECT; DENGUE; DENGUE VIRUS; ENVELOPE GENE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE MICROSCOPY; HUMAN; IMMUNODETECTION; INSECT CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; SERUM; SYNCYTIUM; VIRUS STRAIN; YELLOW FEVER FLAVIVIRUS; ANIMAL; BLOOD; CELL FUSION; CULTURE TECHNIQUE; GENE VECTOR; GENETICS; IMMUNOLOGY; INSECT; METABOLISM; YELLOW FEVER;

DENGUE VIRUS; EUKARYOTA; FLAVIVIRIDAE; FLAVIVIRUS; HEXAPODA; YELLOW FEVER VIRUS;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BACULOVIRIDAE; CELL CULTURE TECHNIQUES; CELL FUSION; GENETIC VECTORS; HUMANS; INSECTS; RECOMBINANT PROTEINS; SERUM; VIRAL ENVELOPE PROTEINS; YELLOW FEVER; YELLOW FEVER VIRUS;

EID: 79957525098     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-261     Document Type: Article

References (38)

1. Febre amarela: reflexes sobre a doença, as perspectivas para o século XXI e o risco da reurbanização. PFC Vasconcelos, Rev Bras Epidemiol 2002 5 3 244 258 10.1590/S1415-790X2002000300004
2. Comparative phylogenies of yellow fever isolates from Peru and Brazil. JE Bryant ADT Barrett, FEMS Immunol Med Microbiol 2003 39 103 118 10.1016/S0928-8244(03)00238-4 14625093 (Pubitemid 37415075)
3. Situação da Febre Amarela Silvestre no Brasil, 2007 e 2008. http://portal.saude.gov.br/portal/arquivos/pdf/boletim-svs-febre-amarela-040408. pdf
4. Dengue: a review of the laboratory tests a clinician must know to achieve a correct diagnosis. SO De Paula BAL Fonseca, Braz J Infect Dis 2004 8 6 390 398 15880229
5. Febre amarela. PFC Vasconcelos, Rev Soc Bras Med Trop 2003 36 2 275 293 10.1590/S0037-86822003000200012 12806465
6. CM Fauquet MA Mayo J Maniloff U Desselberger LA Ball, Virus Taxonomy: eighth report of the International Committee on Taxonomy of Viruses San Diego: Elsevier Academic Press 2005
7. Design, Synthesis, and Biological Evaluation of Thiazoles Targeting Flavivirus Envelope Protein. AS Mayhob M Khaliq RJ Kuhn M Cushman, J Med Chem 2011 54 1704 1714 10.1021/jm1013538 21355607
8. Domain III peptides from flavivirus envelope protein are useful antigens for serologic diagnosis and targets for immunization. JH Chávez JR Silva AA Amarilla LTM Figueiredo, Biologicals 2010 38 613 618 10.1016/j.biologicals. 2010.07.004 20817489
9. Expression of Foreign Protein Epitopes at the Surface of Recombinant Yellow Fever 17D Viruses Based on Three-Dimensional Modeling of its Envelope Protein. MC Bonaldo RC Garratt MS Freire R Galler, Cell Biochemistry and Biophysics 2006 44 313 324 10.1385/CBB:44:3:313 16850531 (Pubitemid 43780387)
10. Yellow Fever: A Reemerging Threat. CL Gardner KD Ryman, Clin Lab Med 2010 30 237 260 10.1016/j.cll.2010.01.001 20513550
11. Baculovirus Molecular Biology. GF Rohrmann, Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information 2008 http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=bacvir
12. Assessment of the application of baculoviruses for control of Lepidoptera. F Moscardi, Annu Rev Entomol 1999 44 257 289 10.1146/annurev.ento. 44.1.257 15012374 (Pubitemid 29096973)
13. DR O'Reilly LK Miller VA Luckow, Baculovirus Expression Vectors: A Laboratory Manual New York: W.H. Freeman and Company 1992
14. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. TA Kost JP Condreay DL Jarvis, Nat Biotechnol 2005 23 5 567 575 10.1038/nbt1095 15877075 (Pubitemid 41724895)
15. Insecticidal activity of two proteases against Spodoptera frugiperda larvae infected with recombinant baculoviruses. AW Gramkow S Perecmanis RLB Sousa EF Noronha CR Felix T Nagata BM Ribeiro, Virol J 2010 29 7 143
16. A new insect cell line from Trichoplusia ni (BTI-Tn-5B1-4) susceptible to Trichoplusia ni single nuclear polyhedrosis virus. RR Granados L Guoxun ACG Derskse KAA Mckenna, J Invertebr Pathol 1994 64 260 266 10.1016/S0022-2011(94) 90400-6 (Pubitemid 124014007)
17. Molecular Cloning: a laboratory manual. J Sambrook EF Fritsch T Maniatis, New York: Cold Spring Harbor Laboratory Press 1989
18. Processing of yellow fever virus polyprotein: role of cellular proteases in maturation of the structural proteins. A Ruiz-Linares A Cahour P Després M Girard M Bouloy, J Virol 1989 63 10 4199 4209 2674479 (Pubitemid 19229415)
19. Baculovirus vectors for multiple gene expression and for occluded virus production. X Wang BG Ooi LK Miller, Gene 1991 100 131 137 2055465
20. Cleavage of structural proteins during assembly of the head of bacteriophage T4. UK Laemmli, Nature 1970 227 680 685 10.1038/227680a0 5432063
21. Monoclonal antibodies distinguish between wild and vaccine strains of yellow fever virus by neutralization, hemagglutination inhibition, and immune precipitation of the virus envelope protein. JJ Schlesinger MW Brandris TP Monath, J Virol 1983 125 1 8 17 10.1016/0042-6822(83)90059-4 (Pubitemid 13149559)
22. MAC-ELISA and ELISA inhibition methods for detection of antibodies after yellow fever vaccination. S Vázquez O Valdés M Pupo I Delgado M Álvarez JL Pelegrino MG Guzmán, J Virol Methods 2003 110 2 179 184 10.1016/S0166-0934(03)00128-9 12798246 (Pubitemid 36645262)
23. Expression of the yellow fever virus envelope protein using hybrid SV40/yellow fever viruses. P Desprès A Cahour C Wychowski M Girard M Bouloy, Ann Inst Pasteur Virol 1988 139 1 59 67 10.1016/0769-2609(88)90097-X 3061412 (Pubitemid 18079639)
24. Biological and immunological characterization of recombinant Yellow Fever 17D Viruses expressing a Trypanosoma cruzi Amastigote Surface Protein-2 CD8+ T cell epitope at two regions of the genome. RT Nogueira AR Nogueira MCS Pereira MM Rodrigues R Galler MC Bonaldo, Virol J 2011 8 127 140 10.1186/1743-422X-8-127 21418577
25. Replication-defective adenoviral vaccine vector for the induction of immune responses to Dengue virus type 2. S Jaiswal N Khanna S Swaminathan, J Virol 2003 77 23 12907 12913 10.1128/JVI.77.23.12907-12913.2003 14610213 (Pubitemid 37430686)
26. Comparison of Escherichia coli, Saccharomyces cerevisiae, Pichia pastoris, Spodoptera frugiperda, and COS7 Cells for Recombinant Gene Expression: Application to a Rabbit Liver Carboxylesterase. CL Morton PM Potter, Mol Biotech 2000 16 3 193 202 10.1385/MB:16:3:193 (Pubitemid 32217198)
27. Yellow fever. TP Monath, Medicine 2005 33 7 21 23 10.1383/medc.2005.33.7. 21
28. Yellow fever: epidemiology and prevention. ED Barnett, Clin Infect Dis 2007 44 6 850 856 10.1086/511869 17304460 (Pubitemid 46365314)
29. Recombinant baculoviruses expressing yellow fever virus E and NS1 proteins elicit protective immunity in mice. P Desprès J Dietrich M Girard M Bouloy, J Gen Virol 1991 72 2811 2816 10.1099/0022-1317-72-11-2811 1834798
30. 17D yellow fever vaccine virus envelope protein expressed by recombinant baculovirus is antigenically indistinguishable from authentic viral protein. SYW Shiu S Morikawa A Buckley S Higgs V Karunakarannair C Blachere EA Gould, J Gen Virol 1991 72 1451 1454 10.1099/0022-1317-72-6-1451 1710651
31. Risk of fatal adverse events associated with 17DD yellow fever vaccine. CJ Struchiner PM Luz I Dourado HK Sato SG Aguiar JG Ribeiro RC Soares CT Codeço, Epidemiol Infect 2004 132 5 939 946 10.1017/S0950268804002602 15473158 (Pubitemid 39307352)
32. Persistance long terme des anticorps neutralisants de la fièvre jaune chez les personnes gées de 60 ans et plus: Long term persistance of yellow fever neutralising antibodies in elderly persons. HC Bodilis G Benabdelmoumen A Gergely C Goujon M Pelicot P Poujol PH Consigny, Bull Soc Pathol Exot 2010 1 1 6
33. Eventos adversos pás-vacinação com a vacina contra febre amarela. http://portal.saude.gov.br/portal/arquivos/pdf/nota-FA-19112007. pdf
34. An Inactivated Cell-Culture vaccine against Yellow Fever. TP Monath E Fowler CT Johnson J Baiser MJ Morin M Sisti DW Trent, N Engl J Med 2011 364 14 1326 1333 10.1056/NEJMoa1009303 21470010
35. Is it time for a new yellow fever vaccine? EB Hayes, Vaccine 2010 28 8073 8076 10.1016/j.vaccine.2010.10.015 20971115
36. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. FS Quan C Huang RW Compans SM Kang, J Virol 2007 81 7 3514 3524 10.1128/JVI.02052-06 17251294 (Pubitemid 46456660)
37. A highly specific and sensitive sandwich blocking ELISA based on baculovirus expressed pseudorabies virus glycoprotein B. M Gut-Winiarska L Jacobs H Kerstens K Bienkowska-Szewczyk, J Virol Methods 2000 88 63 71 10.1016/S0166-0934(00)00178-6 10921843 (Pubitemid 30642843)
38. Cervarix suspension for injection - Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed). European Medicines Agency, European public assessment Reports http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/000721/WC500024632.pdf